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The STAR trial is a UK randomized phase II/III study of
first-line sunitinib in locally advanced/metastatic clear
cell renal carcinoma (mRCC). It compares the utilization
of a sunitinib conventional continuation strategy (CCS)
with an experimental sunitinib drug-free interval strat-
egy (DFIS).
Sunitinib is approved for the first-line treatment of
mRCC and convention dictates that it is continued until
disease progression or unacceptable toxicity. Duration of
chemotherapy is frequently determined by cumulative
toxicity, but this is not necessarily the case for targeted
therapies, and the default has previously been to continue
these treatments for longer. A DFIS has the potential
advantage of improved quality of life (QoL) and cost-
effectiveness, due to longer time-periods off-treatment.
The STAR trial is unique in determining whether QoL
benefits from a DFIS can offset any potential detriment
in overall survival (OS). Endpoints will assess both survi-
val and QoL separately, but will also assess averaged
QALY (quality of life year).
Temporarily stopping a treatment, which is working, is
recognized to be potentially challenging for patients, and
a qualitative substudy will be performed alongside the
phase II trial, to explore patient feelings regarding trial
entry and stopping treatment. Results from this will
inform recruitment strategies in phase III.
The multi-stage design maximizes resource efficacy by
facilitating a seamless transition between the phase II
and III parts, assuming attainment of the phase II end-
points (recruitment rate and time to strategy failure). It
also enables the QALY data from the initial phase II
part of the trial to be used to inform and verify the
powering of the overall phase III trial, as minimal data
was available during initial trial design to power on a
QALY outcome.
Other novel outcome measures (time to strategy fail-
ure and summative progression free interval) have also
been required, due to the intermittent nature of the
DFIS reducing the utility of the standard progression
free survival endpoint. With increasing use of targeted
therapies and interest in DFIS due to potential QoL and
cost effectiveness benefits, these novel endpoints will be
increasing required in future clinical trial designs.
The STAR trial will be an exemplar trial in the evalua-
tion of optimal treatment strategies for targeted thera-
pies in other diseases. We will discuss issues relating to
the trial design and the methodology relating to the
novel endpoints in this study, as well as comment on
the implications for future trial design.
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